Fuda Cancer Hospital
Coronary angiography in China typically costs from $2,200 to $4,200. The final price depends on the hospital tier, city, and whether the procedure is invasive or a CT scan. In the US, patients pay $14,500 on average. China offers savings of approximately 78%. This diagnostic usually includes the procedure, local anesthesia, and a short observation period.
Bookimed Expert Insight: Choosing a JCI-accredited facility like Fuda Cancer Hospital ensures adherence to international safety protocols. China remains highly competitive for cardiac diagnostics due to government-regulated pricing in top-tier public hospitals. Recent healthcare reforms have also significantly reduced the cost of cardiac consumables. This makes the country an efficient hub for high-volume vascular interventional therapy.
| China | Turkey | Austria | |
| Coronary angiography | ≈ $2,200 | from $1,800 | ≈ $3,200 |
No hidden fees – just official clinic prices. Pay at the clinic for Coronary angiography upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Coronary angiography and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Coronary angiography journey.
Day 1: Arrival
Day 2: Pre-operation
Day 3: Coronary angiography
Day 4: Post-operation
Day 5: Discharge and Rehabilitation
Week 2
Please note that each patient"s experience may vary, and it"s important to follow your doctor"s advice for a successful recovery.
Dr. Shen Yuqin, MD, PhD, is Professor and Chief Physician at Shanghai Tongji Hospital. Dr. Shen directs the Rehabilitation Medicine Center and the Cardiac Rehabilitation Department. A doctoral supervisor and National Advanced Worker, Dr. Shen is a pioneer in cardiac rehabilitation for heart failure.
Dr. Shen was the first in China to implement cardiopulmonary exercise testing (CPET)-guided rehabilitation for heart failure. Dr. Shen also introduced the use of the anaerobic threshold to prescribe exercise intensity. The team created a nationwide hospital–community–home closed-loop model. In 2020, they opened Shanghai’s only inpatient cardiac rehabilitation ward in a tertiary hospital.
Dr. Shen is the principal investigator of two NSFC General Projects. Honors include the CRMA Science and Technology Award, First Prize (2019), and the Shanghai Rehabilitation Medicine Science and Technology Progress Awards, First Prize (2018, 2024). Dr. Shen has published over 50 papers as first or corresponding author. Dr. Shen served as chief editor of one monograph and associate editor of two. The portfolio includes 22 patents (15 authorized, including three invention patents) and five software copyrights. Nine technology transfers have been completed.
Dr. Shen is a Fellow of the American Association of Cardiovascular and Pulmonary Rehabilitation (FAACVPR) and a CDQI certified expert. Dr. Shen serves as an associate editor and editorial board member. Dr. Shen led the drafting of eight consensuses, guidelines, and standards, and organized 20 national courses. The center has served more than 10,000 patients. The care model has been extended across Shanghai and introduced in Yunnan.
Dr. Xu Juntang, MD, is a Postdoctoral Fellow, Chief Physician, and Master’s Supervisor. He is the Director of Cardiovascular Medicine at Xiamen Humanity Hospital. His work focuses on preventing and treating cardiovascular and thrombotic diseases, including coronary artery disease, hypertension, heart failure, arrhythmias, and emergencies. He is skilled in cardiovascular biomarker testing.
He provides standardized care for thromboembolism related to valvular heart disease and non‑valvular atrial fibrillation, pulmonary embolism, deep vein thrombosis, and obstetric thrombophilia. He also conducts clinical and laboratory assessments of thrombosis and coagulation disorders. He is the Vice Chairman of the Laboratory and Clinical Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesiology.
Dr. Niu Lizhi is the President and chief surgeon at Fuda Cancer Hospital in Guangzhou. He has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures. Dr. Niu specializes in minimally invasive oncology for lung, pancreatic, and liver cancers. He treats patients ranging from early childhood through age 94.